Compounded Tirzepatide vs. Zepbound: Prices, FDA Rules and Lilly's Court Cases
What the published prices show, what FDA approval does and does not cover, and what two separate Eli Lilly court cases actually decided. Every figure and every legal statement is tied to a dated source checked on November 5, 2026.
Sources checked Rechecked monthly
By Open Water Rx Editorial Team. Facts and price sources checked . Published .
GLP1 Buyer Guide and Surfbound Health are operated by Open Water Rx LLC. Surfbound appears in the price examples below. This is the publisher’s research, not independent third-party coverage of Surfbound. Read our ownership disclosure.
What buyers need to know
Zepbound is an FDA-approved tirzepatide medicine. Compounded tirzepatide preparations are not FDA-approved finished products. Comparing their prices does not establish that they work the same. Two different legal disputes also matter: one restricted a particular seller’s advertising; the other upheld the FDA’s decision that the national tirzepatide shortage had ended. [S1][S2][S3]
What is different about the products?
FDA approval covers a particular drug product, not just a name on an ingredient list. FDA does not review compounded preparations for safety, effectiveness or quality before they reach patients. A prescription or a pharmacy’s license does not turn a compounded preparation into an FDA-approved medicine. [S3]
| Question | Zepbound | Compounded tirzepatide |
|---|---|---|
| FDA-approved finished product? | Yes. | No. |
| Is it the Lilly-branded product? | Yes. | No. |
| What should the buyer verify? | The exact product, prescribed dose, pharmacy price and coverage. | The dispensing pharmacy, exact preparation, prescription basis and total program charges. |
Sources for the approval and product distinctions: [S2][S3] The final row is a buyer verification checklist, not a product-quality finding.
What do the published prices show?
These are selected public cash-price examples checked November 5, 2026, not a market-wide ranking or a guarantee that someone qualifies. They cover injectable products only. A medicine-only price and a treatment bundle do not include the same services.
| Program or product | Published price | Period and important terms |
|---|---|---|
| Zepbound single-patient-use KwikPenTirzepatide, FDA-approvedLilly, Zepbound savings and insurance options | Regular published prices
| Per 28-day supply. The 2.5 mg dose is for starting treatment, not maintenance. Lilly also publishes a conditional $449 offer for 7.5 to 15 mg; continued eligibility requires a refill purchase within 45 days of the previous delivery or receipt. Eligibility restrictions apply. Additional taxes and fees may apply. |
| EmergeCompounded injectable tirzepatide, not FDA-approvedEmerge Weight Loss, pricing | Published plan charges
| Every four weeks. The listed plan includes medicine, prescription, medical oversight and shipping. No separate signup or doctor fee is listed. |
| Surfbound HealthCompounded injectable tirzepatide, not FDA-approved. Operated by this publication’s owner.Surfbound Health, pricing | Published plan charge
| Every four weeks (28 days). Provider review, medication if prescribed and shipping are included, with no separate membership fee. This row does not establish which doses an individual can receive. |
Lilly’s advertised medicine price does not establish the cost of obtaining a prescription. Insurance, savings-program eligibility and any additional service fees can change a person’s final bill. The comparison above does not assume that the highest brand price applies to everyone or that the lowest starting price lasts throughout treatment. [S4]
Four weeks is 28 days, not a calendar month. Twelve 28-day supplies cover 336 days. This table reports the actual advertised charge and period rather than calling it a calendar-month price. No annual cost or savings percentage is added here without explicit assumptions.
Did Lilly win a ban on comparing compounded drugs?
The Totality Medispa order did not create an industry-wide ban on comparisons. Lilly and Totality agreed to a settlement, and a federal judge signed the resulting injunction on May 15, 2024; it was filed May 16. An injunction is a court order. [S1]
Paragraph 8(b)(6) bars Totality from saying that its compounded products contain an ingredient that is the same as an ingredient in a Lilly product. The order covers Totality and the related people and participants it identifies. It also addresses misleading branding, FDA-approval claims and claims based on Lilly’s trial results. It is not a laboratory comparison of all compounded products. [S1]
The judgment is a copy hosted by Partnership for Safe Medicines. Read the paragraph 8(b)(6) text on page 4 or the signature page.
What happened in the separate FDA shortage case?
FDA first declared the tirzepatide injection shortage resolved on October 2, 2024, then confirmed that decision on December 19 after reviewing it again. This removed the shortage-based basis for routine copy compounding, subject to the transition policies and other rules FDA describes. [S7]
On August 27, 2026, the Fifth Circuit affirmed the judgment in Outsourcing Facilities Association v. FDA, No. 25-10600. Lilly participated in support of FDA. The dispute concerned FDA’s shortage decision, not proof that a particular compounded prescription matches Zepbound. [S2]
The opinion also discusses FDA’s expectation that limiting compounding could affect demand for Lilly’s drugs. It notes that price, insurance, off-label use and other manufacturers’ marketing made the amount of switching uncertain. It does not establish a profit motive for the decision. [S2]
Can websites still make factual comparisons?
The FTC supports truthful, non-misleading comparative advertising with a clear basis for the comparison. That does not override drug-marketing rules or a court order. [S8]
Separately, FDA said in February 2026 that promotional material cannot present compounded GLP-1 products as approved-drug generics or as the same products, claim the same active ingredient, or transfer clinical-results claims to compounded products. Reporting what a court document says is different from making those claims about a product being sold. [S9]
Does a prescription automatically make compounding lawful?
No. FDA describes several conditions for the patient-specific compounding pathway called section 503A. These include restrictions on regularly making copies of commercially available drugs. A prescriber-documented change that makes a significant difference for an identified patient can matter, but a prescription alone does not establish that every condition is satisfied. [S7]
Are research-use peptides another prescription option?
A research label is not evidence that a product is a medicine for patients. FDA has warned about unapproved products labeled for research or not for human consumption while being sold for human use. They should not be presented as interchangeable with prescribed compounded preparations or approved medicines. [S3]
What should you ask before choosing a provider?
Ask which exact product would be prescribed and which pharmacy would dispense it. Get the full charge, the number of days supplied, any required membership or consultation fees, and the cancellation terms. For a compounded prescription, ask the prescriber to explain the patient-specific reason and the pharmacy to identify the preparation. A price comparison cannot answer those clinical and dispensing questions for you. [S3][S7]
How this article was checked
This report separates court orders, FDA statements, FTC policy and providers’ own price claims. The three price examples were selected to show a branded medicine price, a dose-tiered compounded program and a flat-price compounded program. They are not a representative sample or a ranking. The publisher also operates Surfbound. No medication was purchased or laboratory-tested for this article. A source link documents what a source says; it is not an endorsement of every claim on that source’s website.
For broader program records, use our comparison ledger. To report a factual error, use our corrections page.
Sources
Every entry was read on November 5, 2026. Where a document is hosted by a third party, the host is named in the entry and is not responsible for this article’s interpretation.
- S1
Final Judgment and Permanent Injunction, Eli Lilly and Company v. Totality Medispa LLC, No. 2:23-cv-04697-RMG (Entry 38). U.S. District Court for the District of South Carolina. Signed May 15, 2024; filed May 16, 2024.
Relevant: paragraphs 5 to 8 and the signature page. This is a copy of the court document hosted by Partnership for Safe Medicines, not that organization’s independent legal interpretation.
https://www.safemedicines.org/wp-content/uploads/2024/05/Judgment-Eli-v-TotalityMedispa-May-2024.pdfParagraph 8(b)(6), page 4Signature page, page 5Return to the summary
- S2
Outsourcing Facilities Association v. FDA, No. 25-10600, opinion. U.S. Court of Appeals for the Fifth Circuit. August 27, 2026. Designated unpublished..
Relevant: pages 1 to 7 and page 28. On page 7 the court assumes a possible procedural error without deciding it, then finds no demonstrated prejudice, so this article does not describe the ruling as deciding that notice and comment were unnecessary.
https://www.ca5.uscourts.gov/opinions/unpub/25/25-10600.0.pdfPage 28, the demand and switching paragraphReturn to the summary
- S3
FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. U.S. Food and Drug Administration. Read November 5, 2026.
Relevant: approval status, patient recommendations, and the warning about products labeled for research use only.
https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-lossReturn to the product comparison
- S4
Zepbound Savings & Insurance Options. Eli Lilly and Company. Read November 5, 2026.
Regular single-patient-use KwikPen prices and the applicable purchase-offer terms. These are not all-in telehealth plan prices, and a price for another device is not used here.
https://zepbound.lilly.com/savingsReturn to the price examples
- S5
Pricing. Emerge Weight Loss. Read November 5, 2026.
Its published injectable-plan charges, not referral coupons, oral products or the separate maintenance program.
https://www.emergeweight.com/pricingReturn to the price examples
- S6
Pricing. Surfbound Health. Read November 5, 2026.
The page explains that four weeks means 28 days and four weekly doses. This article uses that clarification rather than reading its shorthand "monthly" as a calendar month.
- S7
FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. U.S. Food and Drug Administration. October 2024 and December 2024 decisions, with a clarification dated April 1, 2026. Read November 5, 2026..
Relevant: the tirzepatide shortage decisions, the transition policies, and the conditions FDA describes for the patient-specific pathway in section 503A.
https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilizeReturn to the shortage case
- S8
Statement of Policy Regarding Comparative Advertising. U.S. Federal Trade Commission. August 13, 1979.
The policy statement on truthful, non-misleading comparative advertising with a clear basis for the comparison.
https://www.ftc.gov/legal-library/browse/statement-policy-regarding-comparative-advertisingReturn to the advertising section
- S9
FDA Intends to Take Action Against Non-FDA-Approved GLP-1 Drugs. U.S. Food and Drug Administration. February 6, 2026.
FDA’s stated enforcement position, which is separate from the Totality court order and from the shortage litigation.
https://www.fda.gov/news-events/press-announcements/fda-intends-take-action-against-non-fda-approved-glp-1-drugsReturn to the advertising section
Cite this report
GLP1 Buyer Guide. "Compounded Tirzepatide vs. Zepbound: Prices, FDA Rules and Lilly's Court Cases." Open Water Rx Editorial Team, publisher Open Water Rx LLC. Sources checked November 5, 2026. Published November 5, 2026. Last modified November 5, 2026. https://glp1buyerguide.com/articles/compounded-tirzepatide-vs-zepbound
This article records what the named sources said on the dates shown. It is not medical or legal advice, and it does not recommend a program. Prices, terms and court dockets change; confirm them at the source before you rely on them.
Last modified . Facts carry the date we checked the provider page behind them.